Trial Profile
Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer
- Focus Therapeutic Use
- 16 Aug 2012 New trial record